Changes in BNP, hs-CRP and TIMI risk index with addition of tirofiban during primary percutaneous coronary intervention for acute STEMI: A prospective observational cohort study;Akut STEMI'de primer perkütan koroner girişiminde tedaviye tirofibanın eklenmesi durumunda, TIMI risk indeksi, BNP ve hs-CRP deǧerlerindeki deǧişimi

Anadolu Kardiyoloji Dergisi

Volumn 12, Issue 2, 2012, Pages 107-114

  Kurt, Ibrahim Halil ^a   Demirkol, Sait ^b   Ünal, Ilker ^c   Batur, Mustafa Kemal ^d  

^a ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c CUKUROVA UNIVERSITY   (Turkey)

^d ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Acute myocardial infarction; B type natriuretic peptide; High sensitive; Percutaneous coronary intervention; TIMI risk index; Tirofiban

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TIROFIBAN; BIOLOGICAL MARKER; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; TYROSINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; TIMI RISK INDEX; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; DRUG ANTAGONISM; HEART INFARCTION; HOSPITALIZATION; INTRAOPERATIVE PERIOD; METABOLISM; MIDDLE AGED; RISK; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; TYROSINE;

EID: 84862679977     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2012.035     Document Type: Article

References (32)

1. Ochiai M, Isshiki T, Takeshita S, Oshima A, Toyoizumi H, Kondo K, et al. Relation of duration of ST re-elevation at reperfusion and improvement of left ventricular function after successful primary angioplasty of the left anterior descending coronary artery in anterior wall acute myocardial infarction. Am J Cardiol 1997; 79: 1667-1670.
2. Kobayashi N, Ohmura N, Nakada I, Yasu T, Iwanaka H, Kubo N, et al. Further ST elevation at reperfusion by direct percutaneous transluminal coronary angioplasty predicts poor recovery of left ventricular systolic function in anterior wall AMI. Am J Cardiol 1997; 79: 862-866.
3. Miida T, Oda H, Toeda T, Higuma N. Additional ST-segment elevation immediately after reperfusion and its effect on myocardial salvage in anterior wall acute myocardial infarction. Am J Cardiol 1994; 73: 851-855.
4. Nguyen CM, Harrington RA. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs 2003; 3: 423-436.
5. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-1453.
6. Giannitsis E, Muller-Bardorff M, Lehrke S, Wiegand U, Tolg R, Weidtmann B, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001; 104: 630-635.
7. Grabowski M, Filipiak KJ, Karpinski G, Wretowski D, Rdzanek A, Huczek Z, et al. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J 2004; 148: 655-662.
8. Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93: 18-23.
9. Kuklinska AM, Sobkowicz B, Mroczko B, Sawicki R, Musial WJ, Knapp M, et al. Prognostic significance of the admission plasma B-type natriuretic peptide measurement in patients with first ST-elevation myocardial infarction in comparison with C-reactive protein and TIMI risk score. Clin Chim Acta 2007; 382: 106-111.
10. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44: 335-339. [CrossRef]
11. Krumholz HM, Anderson JL, Brooks NH, Fesmire FM, Lambrew CT, Landrum MB, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the ACC/AHA Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction) Circulation 2006; 113: 732-761. [CrossRef]
12. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I findings. N Engl J Med 1985; 312: 932-936.
13. Holmes DR Jr, Holubkov R, Vlietstra RE, Kelsey SF, Reeder GS, Dorros G, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988; 12: 1149-1155.
14. Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358: 1571-1575.
15. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
16. Warnholtz A, Ostad MA, Heitzer T, Goldmann BU, Nowak G, Munzel T. Effect of tirofiban on percutaneous coronary interventioninduced endothelial dysfunction in patients with stable coronary artery disease. Am J Cardiol 2005; 95: 20-23.
17. V Korn H, Ohlow M, Donev S, Yu J, Huegl B, Wagner A, et al. Export aspiration system in patients with acute coronary syndrome and visible thrombus provides no substantial benefit. Catheter Cardiovasc Interv 2007; 70: 35-42.
18. Erdim R, Erciyes D, Görmez S, Karabay KO, Catakoǧlu AB, Aytekin V, et al. Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention. Anadolu Kardiyol Derg 2010; 10: 340-345.
19. Heestermans AA, Van Werkum JW, Hamm C, Dill T, Gosselink AT, De Boer MJ, et al. Marked reduction of early stent thrombosis with prehospital initiation of high-dose tirofiban in ST-segment elevation myocardial infarction. J Thromb Haemost 2009; 7: 1612-1618.
20. Heestermans AA, Hermanides RS, Gosselink AT, de Boer MJ, Hoorntje JC, Suryapranata H, et al. A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry. Neth Heart J 2010; 18: 592-597.
21. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 1-211.
22. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarctiona convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infracting myocardium early II trial sub study. Circulation 2000; 102: 2031-2037.
23. Kurt IH, Batur MK, Unal I. The effect of Streptokinase therapy in STEMI and conventional therapy in NSTEMI patients on TIMI risk index, BNP, hs-CRP levels. Anadolu Kardiyol Derg; 2011; 11: 530-535.
24. Rathore SS, Weinfurt KP, Gross CP, Krumholz HM. Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? Circulation 2003; 107: 811-816.
25. Suzuki S, Yoshimura M, Nakayama M, Mizuno Y, Harada E, Ito T, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 2004; 110: 1387-1391.
26. de Winter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 2004; 94: 1481-1485.
27. Pietilä K, Harmoinen A, Pöyhönen L, Koskinen M, Heikkila J, Ruosteenoja R. Intravenous streptokinase treatment and plasma C-reactive protein in patients with acute myocardial infarction. Br Heart J 1987; 58: 225-259.
28. Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Andrikopoulos GK, Olympios CD. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002; 144: 782-789.
29. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, Katsaros K, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533-537.
30. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Eng J Med 2005; 352: 20-28.
31. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Eng J Med 2005; 352: 29-38.
32. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.